Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Regains Compliance With Rules for Nasdaq Listing

NEW YORK ─ Molecular diagnostic company Genetic Technologies said on Tuesday it received notification from the Nasdaq Stock Market that it now meets a minimum stockholders equity requirement for continued listing of its American Depositary Shares (ADSs) on the Nasdaq.

Melbourne, Australia-based Genetic Technologies, a developer of genetic risk assessment tests, noted that since April 2020, it had raised a total of about $16.4 million through offerings of its American Depositary Shares and it had stockholders' equity in excess of $2.5 million as of Aug. 28, in compliance with Nasdaq's listing rule.

The firm, a developer of predictive testing and assessment tools for cancers, said in March it had received a notice that it is out of compliance with the Nasdaq's continued listing requirements.

In July, the firm announced it inked definitive agreements to sell $5.1 million worth of ADSs to institutional investors.

The firm had also lost and regained compliance with Nasdaq listing requirements in 2019 and 2018.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.